nivolumab,ipilimumab
bms
[]
ifct 1701:: non inferiority but stopped early for regulatory reasons at n=265 (planned &gt;1300); stop and go arm = less toxic; #esmo22 
Consultant Medical Oncologist, UK. Views are hypothesis generating discourse. Post COVID dabbling in garden.